Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study
Carregando...
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Citação
EXPERIMENTAL AND THERAPEUTIC MEDICINE, v.8, n.4, p.1205-1208, 2014
Resumo
Lithium has a narrow therapeutic index with a subtle balance between effectiveness and adverse effects. Current guidelines recommend the use of lithium as a treatment for acute bipolar depression; however, the therapeutic range for the treatment has not been fully defined. Recently, the adjunctive lower lithium dose in bipolar depression has revealed potential efficacy; however, no study has investigated it predominantly in monotherapy. In this open-label, proof-of-concept study, 31 individuals with bipolar disorder during a depressive episode were randomized and 29 were followed up for six weeks with flexible lithium dosing. All subjects had a 21-item Hamilton Rating Scale for Depression (HAM-D) score of >= 18 at baseline. Subjects were divided into two groups, with higher (Li >= 0.5 mEq/l) or lower (Li <0.5 mEq/l) blood lithium levels. Response and remission rates were evaluated using the HAM-D scores. Following 6 weeks of lithium treatment, the remission rate for all patients was 62.0%. The plasma lithium levels did not impact the clinical response. However, subjects with higher blood lithium levels had an increased prevalence of nausea, restlessness, headaches and cognitive complaints. The results indicate that the lithium dose for the treatment of bipolar depression in an individual should be based on the clinical efficacy and side-effects. In the context of personalized psychiatric treatments, it is necessary to evaluate the therapeutic action of lithium with individual regimens in order to develop more tolerable and effective treatment approaches.
Palavras-chave
bipolar disorder, depression, lithium, treatment, trial
Referências
- Amsterdam JD, 2008, J CLIN PSYCHOPHARM, V28, P171, DOI 10.1097/JCP.0b013e318166c4e6
- COPPEN A, 1983, J AFFECT DISORDERS, V5, P353, DOI 10.1016/0165-0327(83)90026-5
- First M. B., 1995, STRUCTURED CLIN INTE
- Forlenza OV, 2012, DRUG AGING, V29, P335, DOI 10.2165/11599180-000000000-00000
- GELENBERG AJ, 1989, NEW ENGL J MED, V321, P1489, DOI 10.1056/NEJM198911303212201
- Haeberle A, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-153
- Judd LL, 2003, ARCH GEN PSYCHIAT, V60, P261, DOI 10.1001/archpsyc.60.3.261
- Machado-Vieira R, 2009, BIPOLAR DISORD, V11, P92, DOI 10.1111/j.1399-5618.2009.00714.x
- Merikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P543, DOI 10.1001/archpsyc.64.5.543
- Nierenberg AA, 2013, AM J PSYCHIAT, V170, P102, DOI 10.1176/appi.ajp.2012.12060751
- Nolen WA, 2013, BIPOLAR DISORD, V15, P100, DOI 10.1111/bdi.12027
- Perlis RH, 2002, AM J PSYCHIAT, V159, P1155, DOI 10.1176/appi.ajp.159.7.1155
- Severus WE, 2008, BIPOLAR DISORD, V10, P231, DOI 10.1111/j.1399-5618.2007.00475.x
- Suppes T, 2008, J AFFECT DISORDERS, V111, P334, DOI 10.1016/j.jad.2008.02.004
- Yatham LN, 2013, BIPOLAR DISORD, V15, P1, DOI 10.1111/bdi.12025
- Young AH, 2010, J CLIN PSYCHIAT, V71, P150, DOI 10.4088/JCP.08m04995gre